The most studied inhibitor of EZH2 is 3-deazanoplanocin A (DZNep), with numerous studies demonstrating its ability to decrease GBM cell self-renewal and viability in vitro and decrease tumor growth in vivo (14, 19, 131, 132, 190, 192). This evidence concerns the gene EZH2 and glioblastoma.